{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:00:55Z","timestamp":1787169655759,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To assess the diagnostic accuracy of forced eyelid closure test (FECT), ice pack test (IPT), repetitive nerve stimulation test (RNS), and acetylcholine receptor (AchR) antibody test in patients with suspected ocular myasthenia. To assess the clinical utility of AchR antibody test in predicting disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective cohort study of patients diagnosed with ocular myasthenia at a South-Indian neuro-ophthalmology tertiary eye clinic. Baseline characteristics; ocular myasthenia symptoms; results of FECT, IPT, RNS, and AchR antibody test; and progression time to generalized myasthenia (GM) over 36 months from the time of diagnosis were recorded and analyzed using receiver operator curve analysis, multiple logistic regression, and Kaplan\u2013Meier survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      FECT had a sensitivity of 96.7% (95% CI: 88.5\u201399.6) and a specificity of 75% (95% CI: 34.9\u201396.8). Combination of FECT and IPT, using the positivity of at least one test, increased the sensitivity to 98.3% (95% CI: 91\u2013100), reducing the specificity to 50% (95% CI: 15.7\u201384.3), whereas using the positivity of both tests, we obtained a sensitivity of 71.7% (95% CI: 58.6\u201382.5) and a specificity of 100% (95% CI: 63.1\u2013100). In the subset of patients with double negative RNS and AchR antibodies, the positive predictive value of combined FECT and IPT (double positive) was 100%. Patients who developed GM were more likely to have a positive AchR antibody test result (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001)\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Combined FECT and IPT (double positive) has high diagnostic accuracy even among patients with normal RNS and negative AchR antibodies. Despite low sensitivity, AchR-antibody test has a significant predictive value in disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2015_21","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T07:53:23Z","timestamp":1648454003000},"page":"1331-1337","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Diagnostic accuracy and clinical utility of bed side tests versus laboratory tests in the diagnosis of ocular myasthenia"],"prefix":"10.4103","volume":"70","author":[{"given":"Priya","family":"Sivakumar","sequence":"first","affiliation":[{"name":"Department of Neuro Ophthalmology and Low Vision Services, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivraj","family":"Tagare","sequence":"additional","affiliation":[{"name":"Department of DNB Ophthalmology, Aravind Eye Care, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of DNB Ophthalmology, Aravind Eye Care, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","article-title":"The course of myasthenia gravis and therapies affecting outcome","volume":"505","author":"Grob","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.nrl.0000240856.03505.b5","article-title":"Ocular myasthenia: Diagnosis, treatment, and pathogenesis","volume":"12","author":"Kusner","year":"2006","journal-title":"Neurologist"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICU.0b013e328310da18","article-title":"Medical treatment options for ocular myasthenia gravis","volume":"19","author":"Antonio-Santos","year":"2008","journal-title":"Curr Opin Ophthalmol"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur J Neurol"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S1388-2457(00)00307-2","article-title":"SFEMG in ocular myasthenia gravis diagnosis","volume":"111","author":"Padua","year":"2000","journal-title":"Clin Neurophysiol"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.clinph.2004.05.024","article-title":"Repetitive nerve stimulation in myasthenia gravis \u2013Relative sensitivity of different muscles","volume":"115","author":"Costa","year":"2004","journal-title":"Clin Neurophysiol"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of mysasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","article-title":"Prognosis of ocular myasthenia","volume":"14","author":"Bever","year":"1983","journal-title":"Ann Neurol"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/WNO.0000000000000514","article-title":"Validity of forced eyelid closure test: A novel clinical screening test for ocular myasthenia gravis","volume":"37","author":"Apinyawasisuk","year":"2017","journal-title":"J Neuroophthalmol"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"e1800","DOI":"10.1212\/WNL.0000000000010619","article-title":"Comparison of ice-pack test and single fiber EMG diagnostic accuracy in patients referred for myasthenic ptosis","volume":"95","author":"Giannoccaro","year":"2020","journal-title":"Neurology"},{"key":"B14-20240828","first-page":"257","article-title":"Acetylcholine receptor antibody characteristics in myasthenia gravis, I: Patients with generalized myasthenia or disease restricted to ocular muscles","volume":"49","author":"Vincent","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaneurol.2015.1444","article-title":"Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis","volume":"72","author":"Peeler","year":"2015","journal-title":"JAMA Neurol"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul","year":"2004","journal-title":"J Neurol Sci"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali","year":"2008","journal-title":"Neurology"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2015_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:11:16Z","timestamp":1787166676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2015_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2015_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"2021-08-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}